Friday, 25 June 2010

Sustainable Businesses in the Regenerative Medicine Industry

By Joyce Tait

Successful and sustainable businesses in the Regenerative Medicine industry need to incorporate strategies to address key factors beyond individual business boundaries. These include legal, ethical and financial frameworks, distribution and logistics, and end users willingness to adopt and ability to pay. Business models need to be well adapted to the needs of this market and wil vary depending on whether the end product is a cellular therapy, a delivery system for cells, genes or small molecules or enabling tools and technologies for stimulating endogenous repair. The value systems for each of these types of products are likely to have unique features but will also need to be compliant with global regulatory and legal frameworks.

The REALISE project brings together a UK wide consortium of business and academic partners, with experience of working in innovative technologies and a background in road mapping, assessing, funding and commercialising Regenerative Medicine products. It builds upon some pre-existing work but seeks to create a novel product for wider use.

REALISE is developing a set of software based tools to analyse each step of the value chain from Discovery, through Development to Delivery to the market and impact on the economy. These tools will be validated on a small but diverse set of regenerative medicine products with which the consortium is directly involved so as to define value systems for a more diverse set of products in future.

A generally applicable analysis method, the Therapy Pathway Realisation Tool (TRPT), is being created and its findings made available to the UK Regenerative Medicine industry, its investors and stakeholders to use in developing the value systems, assessing the impact of investment and as an aid to defining business models for its products and services.

The outputs for this project will be
  • Generic business models and business plans and development strategies for three regenerative medicine products which are close to commercialisation.
  • A generally applicable Therapy Pathway Realisation Tool, a software based road mapping and decision making tool. This will allow projects to define their best suited business model, and the opportunity, through interrogation of the Therapy Pathway Realisation Tool, to make Impact Assessments which allow decision making based on issues of strategic and economic impact.
  • Insight into the interaction between business models and regulatory influences within the UK and global value systems.
  • Determination of the availabiliby and influence of private and public sector funding and identifying potential short falls.
Scottish Stem Cell Network with KLCE Consulting Ltd, Roslin Cells Ltd, the ESRC Innogen Centre at the University of Edinburgh and specialist design firm, New Game Plan Ltd, have received Funding from TSB, Scottish Government, the Economic and Social Research Council and Edinburgh Bioquarter, to develop the Therapy Pathway Realisation Tool. The project will be completed within 18 months from May 2010.The knowledge gained by the partners and our collaborators will form the basis of a generic tool with wider applicability across the pharmaceutical, medical device and diagnostic sectors.

The £444,000 award was made under the Technology Strategy Board Regenerative Medicine Programme: Value Systems and Business Models.

3 comments:

Anonymous said...

Hi there, I found your blog via Google blogsearch and your post is very interesting. Thank you.

Check this out too:
Medisoft

Unknown said...

For all who have lost the shine and softness of the skin with the progressing age, advanced and exciting therapy involving regenerative medicines awaits to wonder. It all now takes an expert’s advice besides few Co2 Fractional Laser therapy sessions at MetroMD to help you regain your beautiful self again!

mouse said...

Each product system has its value purpose, like a cellular therapy, a delivery system for cells, genes or small molecules or enabling tools and technologies for stimulating endogenous repair,genome engineering using the crispr cas9 system.